Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population

详细信息    查看全文

• 作者：Pasi P. Karjalainen ; Antti-Pekka Annala ; Antti Ylitalo ; Tero Vahlberg ; K.E. Juhani Airaksinen
• 关键词：Titanium-nitride-oxide-coated stent ; Paclitaxel-eluting stent ; Restenosis ; Stent thrombosis
• 刊名：International Journal of Cardiology
• 出版年：2010
• 出版时间：24 September 2010
• 年：2010
• 卷：144
• 期：1
• 页码：42-46
• 全文大小：240 K

文摘

Background

The aim of this study was to evaluate long-term clinical events in patients treated with titanium-nitride-oxide-coated bio-active stents (BAS) and paclitaxel-eluting stents (PES) in routine clinical practice.

Methods

All patients undergoing percutaneous coronary intervention (PCI) were eligible for this single-centre registry between May 2003 and November 2004. The primary end point of the study was major adverse cardiac events (MACE) at 3 years including myocardial infarction (MI), cardiac death and target vessel revascularization (TVR).

Results

A total of 201 patients received BAS and 204 patients PES. In addition, during the same study period, 184 patients were treated with bare-metal stents (BMS) and 125 patients underwent CABG. Complete follow-up datasets were available in all patients. After 3 years of follow-up, the rate of MACE was 13.9 % for BAS and 23.5 % for PES (adjusted HR 2.0, 95 % CI 1.2–3.2, p = 0.006). This difference was mainly driven by a higher incidence of MI in the PES group (19.1 % ) compared with the BAS (7.5 % ) group (adjusted HR 3.2, 95 % CI 1.7–5.8, p < 0.001). The rate of MACE was 31.5 % in the BMS group and 4 % in the CABG group. At 3 years, stent thrombosis occurred in 15 patients in the PES (7.4 % ) group. There was no stent thrombosis in the BAS group.

Conclusions

After the 3 year follow-up, BAS resulted in better long-term outcome compared with PES with infrequent need for TVR.